EVÄVAARA-DESIGN
11.5.2021 12:48:07 CEST | Business Wire | Press release
Remote working has raised a number of challenges that have been taken up by Finnish pioneering designer of functional furniture, Evävaara Design. Evävaara is launching two completely new workstation designs to fit any home: the larger, mobile sshhh 3 and the smaller sshhh 7 . The workstations support the wellbeing of employees with good ergonomic and acoustic design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005612/en/
Antti Evävaara, founder and chief designer of Evävaara Design, has almost twenty years’ experience in designing and producing functional furniture, with solid expertise in good acoustics and user comfort, which provide the basis for their workstation design.
“In today’s world we are constantly surrounded by irritants and noise that can make it hard to focus on something. Our products aim to create a quiet, personal space that allows you to focus”, says Evävaara .
The furniture-shaped workstations designed by Evävaara are a response to the challenges posed by the increase in remote working. According to remote work and virtual leadership expert Ulla Vikman of Timanttia Consulting, those who do a great deal of remote work, often experience interruptions and are sometimes challenged by a blurred line between work and free time.
“Someone who does a great deal of remote work would be distracted if the necessary tools, such as displays and paperwork, are constantly on all over their home. By intruding your thoughts constantly, these things tend to increase stress levels and focusing becomes more difficult”, says Vikman .
The design of Evävaara workstations is focused on a number of details that support concentration and ergonomics. The wood and felt of the workstation muffles both external and internal noise and improves the acoustics of the whole room. Standard equipment for the workstation includes
- Power sockets and cords
- USB port
- LED lights
- Storage pockets for paperwork and other materials
The larger sshhh3 can be purchased with an additional, adjustable chair. After work, the workstation doors are simply closed and the workstation becomes a mobile cabinet. A neutral colour scheme makes the unit blend seamlessly in any home environment.
In order to boost the efficiency of your working day, Evävaara Design workstations are easy to deploy. The workstation is delivered assembled and ready to use. Evävaara Design workstations are available direct from the designer.
Today the products of Evävaara Design are in use all over Europe wherever a calm space is required, for instance in open plan offices and libraries. They have also garnered some international interest since Vincent Gregoire, Nelly Rodi’s creative director and a celebrity in the business, included Evävaara products in a video showcasing new trends at the Maison & Objet fair in February.
More information: https://www.evavaaradesign.com/etatyopisteet/
Evavaara Design is a Finnish pioneer in functional furniture design in Europe – creating quiet corners for every environment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005612/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom